is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.

GIQuIC Automation of Pathology Results

Now from Miraca

Avoid hours of manual data entry! Miraca pathology results now can populate the pathology section of the GIQuIC form automatically if you use gGastro® from gMed, a Modernizing Medicine company, or ProVation® MD from Wolters Kluwer. How is this automation possible? Miraca delivers highly structured pathology results through enhanced interfaces with gMed and ProVation MD,.

gGastro Capabilities

Pathology results for colonoscopies will populate automatically in the GIQuIC form.

ProVation MD Capabilities

Pathology results for single colonoscopies will populate automatically in the GIQuIC form. Additionally, the ProVation MD Adenoma Detection Rate report for physicians can be created automatically.

If your practice participates in the GIQuIC registry, you can avoid hours of manual data entry. Contact Miraca to get started: Call 1.866.588.3280 or email

What is GIQuIC?

The GI Quality Improvement Consortium, Ltd.—GIQuIC—is a non-profit collaboration of the American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE), providing a quality benchmarking registry. Physicians are participating by collecting and submitting data about their colonoscopies. Participation in GIQuIC enables practices and centers to participate in PQRS reporting in order to avoid penalties by the Centers for Medicaid and Medicare Services (CMS).

Miraca Life Sciences provides fee-based consulting services to help clients understand their options for quality reporting and how to embed quality reporting into their practice or center. Quality reporting such as via GIQuIC is required for participation in the CMS programs Value-Based Modifiers and Merit-Based Incentive Payment System (MIPS) as the industry goes to a pay-for-performance model.

Contact Miraca Life Sciences to learn how Miraca can assist your practice
Call 1.866.588.3280 or email

All of our Miraca support reps have helped me understand this [CMS] process.
— Melinda Lomax, CMOM, CPCD, Practice Manager,
Dermatology Center of Atlanta

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News

January 8, 2018

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help […]

Continue reading

November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading

October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading

October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading

September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading